The automated cell counters market in Middle East & Africa is expected to grow from US$ 345.13 million in 2022 to US$ 437.44 million by 2028; it is estimated to grow at a CAGR of 4.0% from 2022 to 2028.
Personalized medicine is an emerging medicinal practice that uses an individual's genetic profile to make decisions about disease prevention, diagnosis, and treatment. Furthermore, knowledge about a patient's genetic profile can help doctors choose the proper medication or therapy and administer it using the appropriate dose or regimen. Stem cells are key tools that fulfill an improved understanding of disease biology as they can be used to study the effect of compounds and the design of innovative biological treatments tailored to individual patient genotypes/phenotypes. Further, the rapidly rising amount of scientific data on stem cell biology is uncovering its role and involvement in the pathogenesis of diverse conditions characterized by tissue degeneration and decreased endogenous healing capabilities. Stem cells and their derivatives are implemented in innovative therapeutic strategies to restore damaged tissues and organs. The increased knowledge of the location and functions of tissue-specific niches guided stem cell research toward the development of novel targeted strategies to heal structures and restore biological functions following tissue injuries and delayed disease progression. The individual response in maintaining stem cell niche integrity and functionality can lead to significant differences in clinical results and therapeutic response/outcomes. Therefore, stem cells are used for the development of personalized medicines according to an individual’s needs. The automated cell counters are used to study the characteristics of these stem cells. The development of personalized medicines is expected to create opportunities for the growth of the automated cell counters market.
Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; MERCK KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott; and Nexcelom Bioscience LLC. are the leading companies operating in the Middle East & Africa automated cell counters market.
Personalized medicine is an emerging medicinal practice that uses an individual's genetic profile to make decisions about disease prevention, diagnosis, and treatment. Furthermore, knowledge about a patient's genetic profile can help doctors choose the proper medication or therapy and administer it using the appropriate dose or regimen. Stem cells are key tools that fulfill an improved understanding of disease biology as they can be used to study the effect of compounds and the design of innovative biological treatments tailored to individual patient genotypes/phenotypes. Further, the rapidly rising amount of scientific data on stem cell biology is uncovering its role and involvement in the pathogenesis of diverse conditions characterized by tissue degeneration and decreased endogenous healing capabilities. Stem cells and their derivatives are implemented in innovative therapeutic strategies to restore damaged tissues and organs. The increased knowledge of the location and functions of tissue-specific niches guided stem cell research toward the development of novel targeted strategies to heal structures and restore biological functions following tissue injuries and delayed disease progression. The individual response in maintaining stem cell niche integrity and functionality can lead to significant differences in clinical results and therapeutic response/outcomes. Therefore, stem cells are used for the development of personalized medicines according to an individual’s needs. The automated cell counters are used to study the characteristics of these stem cells. The development of personalized medicines is expected to create opportunities for the growth of the automated cell counters market.
Market Overview
The Middle East & Africa automated cell counter market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth is attributed to the increasing prevalence of chronic diseases, innovative product launches, and growing research studies across the region. The prevalence of genetic blood disorders is a critical health issue in Saudi Arabia. To control the growing blood disorder, the Saudi Commission for Health Specialties (SCFHS) association council was formed by the Saudi Society for Blood Disorders (SSBD) in 2018. It includes disciplines for adult hematology, pediatric hematology, hemato-pathology, and blood and bone marrow transplant. Further, a continuous rise in chronic diseases, along with high demand for rapid diagnosis, effective treatment options, and preventive measures, are boosting the demand for automated cell counter products in Saudi Arabia. According to WHO, the increasing incidence of viral hepatitis, HIV, and AIDS continues to be a significant health problem in Iran and Qatar. To prevent the growing number of influenza cases, the Public Health Laboratory in Saudi Arabia has fulfilled all the requirements of the WHO to be recognized as a national influenza center for Saudi Arabia. Thus, rising cases of diseases and government initiatives to control the diseases are anticipated to fuel the growth of the automated cell counter market.Middle East & Africa Automated Cell Counters Market Segmentation
The Middle East & Africa automated cell counters market is segmented on the basis of type, end user, and country. Based on type, the market is segmented into hemocytometer, flow cytometers, electrical impedance coulter counters, and spectrophotometers. The spectrophotometers segment held the largest market share in 2022. Based on end user, the market is categorized into hospitals, research laboratories, diagnostics centers, and others. The hospitals segment held the largest market share in 2022. Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market share in 2022.Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; MERCK KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott; and Nexcelom Bioscience LLC. are the leading companies operating in the Middle East & Africa automated cell counters market.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Automated Cell Counters Market - Market Landscape
5. MEA Automated Cell Counters Market - Key Market Dynamics
6. Automated Cell Counters Market - MEA Analysis
7. MEA Automated Cell Counter Market - by Type
8. MEA Automated Cell Counter Market - by End User
9. MEA Automated Cell Counters Market - by Country Analysis
10. Automated Cell Counters Market - Industry Landscape
11. COMPANY PROFILES
12. Appendix
List of Tables
List of Figures
Companies Mentioned
- Eppendorf
- Thermo Fisher Scientific Inc.
- Countstar Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffman-La Roche Ltd
- Beckman Coulter, Inc. (Danaher)
- Nanoentek
- Olympus Corporation
- MERCK KGaA
- Sysmex Corporation
- Agilent Technologies, Inc.
- Abbott
- Nexcelom Bioscience LLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 143 |
Published | October 2022 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 345.13 Million |
Forecasted Market Value ( USD | $ 437.44 Million |
Compound Annual Growth Rate | 4.0% |
Regions Covered | Africa, Middle East |
No. of Companies Mentioned | 13 |